Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in Giant Cell Arteritis
NCT02531633Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of sirukumab in giant cell arteritis (GCA), sponsored by GSK. Started Oct 2015; status: terminated.
02
Drugs
sirukumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT02531633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531633.